Skin barrier repair in post-IPL patients Skin and Connective Tissue Diseases
Conditions
Interventions
Prior to the treatment session, all subjects underwent facial cleansing to remove cosmetics. No topical anesthesia was administered. Subjects received a single IPL treatment session using the BroadBan
commercially available formulation from Galderma®, Inc.) was assigned to one randomly assigned check, while the contralateral side received the reference moisturizer (control
identical base formulation without saccharide isomerate). Follow up for 7 days.
Sponsors
Beijing Tsinghua Chang Gung Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged between 25 and 65 years with Fitzpatrick skin types III-IV 2. Presentation of clinical signs of skin aging 3. Willingness to apply the test moisturizer on the assigned facial side twice daily for 7 consecutive days
Exclusion criteria
Exclusion criteria: 1. Known history of intolerance or hypersensitivity to any component of the test moisturizer 2. Pregnancy, lactation or planning to become pregnant 3. History of systemic phototoxic drug use or any facial laser/energy-based device treatment within the past 6 months 4. Presence of active facial rash, scaling, or edema at the time of screening
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Transepidermal water loss (TEWL) measured using Tewameter® TM HEX probe (Cutometer® dual MPA580 system, Courage + Khazaka) at Baseline (T0), Immediately after first IPL treatment (T1), 1 day (T4), 3 days (T5), 5 days (T6), and 7 days (T7) post-treatment. 2. Skin hydration (SCH - Stratum Corneum Hydration) measured using Corneometer® CM825 probe (Cutometer® dual MPA580 system, Courage + Khazaka) at Baseline (T0), Immediately after first IPL treatment (T1), 1 day (T4), 3 days (T5), 5 days (T6), and 7 days (T7) post-treatment. Erythema Index (EI) measured using Mexameter® MX18 probe (Cutometer® dual MPA580 system, Courage + Khazaka) at Baseline (T0), Immediately after first IPL treatment (T1), 1 day (T4), 3 days (T5), 5 days (T6), and 7 days (T7) post-treatment. 3. Subject satisfaction measured using a subjective questionnaire (assessing moisturizer's performance and purchase intent on a Likert scale) at 7 days post-treatment (T7). 4. Incidence of Treatment-Emergent Adverse Events (TEAEs) assessed by clinical evaluation (including assessment for erythema, edema, blisters, and hyperpigmentation) at All evaluation time points (Baseline (T0), Immediately after first IPL treatment (T1), 1 day (T4), 3 days (T5), 5 days (T6), and 7 days (T7) post-treatment). 5. Visual documentation of skin condition obtained using VISIA®-CR imaging system (Canfield Scientific) under standard and cross-polarized lighting at Baseline (T0), Immediately after first IPL treatment (T1), 1 day (T4), 3 days (T5), 5 days (T6), and 7 days (T7) post-treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| There are no secondary outcome measures | — |
Countries
China
Contacts
Public ContactHui Shao
Outcome results
None listed